Page last updated: 2024-12-06

15-crown-5

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

15-crown-5 is a macrocyclic polyether with the formula (CH2CH2O)5. It is a colorless solid that is soluble in organic solvents. 15-crown-5 is a strong complexing agent for alkali metal ions, particularly potassium ions. This ability stems from its crown-shaped structure, which has five oxygen atoms that can coordinate to the cation. The resulting complex is stabilized by the electrostatic interaction between the positively charged cation and the negatively charged oxygen atoms. This complexation ability is the basis of 15-crown-5's applications. The synthesis of 15-crown-5 involves the reaction of ethylene glycol with pentaerythritol in the presence of a strong acid catalyst. 15-crown-5 is used as a phase-transfer catalyst, a reagent for organic synthesis, and a sensor for alkali metal ions. It is also being studied for its potential applications in the development of ion-selective electrodes, liquid-liquid extraction, and other areas.'

15-crown-5 : A saturated organic heteromonocyclic parent that is cyclopentadecane in which the carbon atoms at positions 1, 4, 7, 10 and 13 have been replaced by oxygen atoms to give a crown ether. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID36336
CHEMBL ID156289
CHEBI ID32401
SCHEMBL ID78595
MeSH IDM0124625

Synonyms (41)

Synonym
1,4,10,13-pentaoxacyclopentadecane
brn 1618144
einecs 251-379-6
ccris 3586
15-crown-5 ether
15-crown-5
CHEBI:32401 ,
33100-27-5
1,4,7,10,13-pentaoxacyclopentadecane
15-crown-5, 98%
10CAF7BC-91EC-44DF-A9EB-501EA2C83E15
15-crown 5-ether
CHEMBL156289
1,4,7,10,13pentaoxa-cyclopentadecane
STK802309
AKOS005622525
A821622
BBL011088
15-crown-5(1,4,7,10,13-pentaoxacyclopentadecane)
5-19-12-00252 (beilstein handbook reference)
FT-0607243
15-crown 5
1,4,7,10,13-pentaoxa-cyclopentadecane
1, 4, 7, 10, 13-pentaoxacyclopentadecane
15c5
SCHEMBL78595
J-503959
DTXSID7067746
mfcd00005110
CS-W007451
15-crown-5, purum, >=98.0% (gc)
15-crown-5, vetec(tm) reagent grade, 98%
SY009952
BCP24526
Q4550134
8-phenyloctanoicacid
EYO ,
AMY25644
[15]crown-5
EN300-6743610
HY-W007451
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
crown etherCrown compounds containing only oxygen as coordinating atom.
saturated organic heteromonocyclic parent
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1614591Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 100 mM in presence of 150 mM Na+ by fluorescence-based assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID50775In vitro lethal dose of compound against Eimeria tenella in chicken kidney cell cultures1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Anticoccidial activity of crown polyethers.
AID1614579Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 6 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614593Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 100 mM in presence of 150 mM K+ by fluorescence-based assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614587Stabilization of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as formation of TTR tetramer band formation at 40 to 100 mM after 4 mins by SDS-PAGE analysis based glutaraldehyde cross-linking assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
AID1614580Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 20 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (3.70)18.7374
1990's2 (3.70)18.2507
2000's16 (29.63)29.6817
2010's31 (57.41)24.3611
2020's3 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.65 (24.57)
Research Supply Index4.09 (2.92)
Research Growth Index5.53 (4.65)
Search Engine Demand Index65.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]